BRIEF—Allergan plans to sell two business units

Ireland-incorporated Botox maker Allergan has completed its strategic review, which was announced earlier this year, and will sell its women's health and infectious disease businesses, sources told the CNBC news service.

A recent note from Cowen analysts, quoted by CNBC, valued the women's health business at $4 billion and the infectious disease business at $2 billion. The units could attract private equity buyers, previous reports have said.

Allergan is trying to right itself after a difficult year. Its shares are down 32% over the last 12 months.

The sale of the units would allow Allergan to refocus on four key areas, including medical aesthetics and dermatology, eye care, central nervous system and gastrointestinal. Proceeds from the sales could be used to pay down debt and buy back shares, said CNBC.